Navigation Links
MicroRNA First Disclosed by Rosetta Genomics may Increase Efficacy of Imatinib (Gleevec(R)(1)) in Glioblastoma
Date:9/18/2008

REHOVOT, Israel and JERSEY CITY, New Jersey, September 18 /PRNewswire-FirstCall/ -- - A Collaborative Study by Scientists at the Weizmann Institute of Science and Scientists at Sheba Medical Center, With the aid of Rosetta Genomics, Demonstrated That Overexpression of miR-451 Inhibited Growth of Glioblastoma (GBM) Cells

- Furthermore, Combining Imatinib (Gleevec(R)), a Targeted Cancer Drug Approved Treatment of Chronic Myelogenous Leukemia (CML) and Gastrointestinal Stromal Tumors Manufactured by Novartis, With miR-451 had a Synergistic Effect in Inhibiting GBM Growth

- miR-451 was First Disclosed in a Patent Application by Rosetta Genomics and is Currently Under Active Examination

Rosetta Genomics, Ltd. (NASDQ: ROSG) announced today that a collaborative study published by scientists from the Weizmann Institute of Science and scientists at Sheba Medical Center, with the aid of Rosetta Genomics, has demonstrated that a microRNA first disclosed by the company increased the efficacy of Imatinib (Gleevec(R)) in Glioblastoma (GBM), the most common and most aggressive type of primary brain tumor.

"We are excited to be part of this important study led by the renowned scientists from the Weizmann Institute of Science and from the Sheba Medical Center," noted Dr. Dalia Cohen, Chief Scientific Officer at Rosetta Genomics. "MicroRNAs are quickly emerging as major regulators of biological processes and have wide diagnostic and therapeutic potential. Rosetta Genomics' extensive intellectual property portfolio which includes the first ever issued patent relating to microRNAs, as well as patent applications for a large portion of today's known microRNAs, positions us to lead the microRNA space and advance patient care worldwide. Our first microRNA-based products, diagnosing various cancers, are expected to be launched later this year."

In the study, "MIR-451 and Imatinib Mesylate Inhibit the Growth of Glioblastoma Stem Cells", published on
'/>"/>

SOURCE Rosetta Genomics Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Rosetta Genomics Identifies Potential microRNA Biomarkers in Blood Serum
2. M. D. Anderson to Initiate Clinical Validation Study on Rosetta Genomics MicroRNA-based Diagnostic Assay Identifying the Origin of Cancer Metastases
3. First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology Receives Regulatory Approval
4. Rosetta Genomics and Collaborators Identify MicroRNAs That Can Accurately Discriminate Between Primary and Metastatic Tumors in the Brain
5. Rosetta Genomics and Rabin Medical Center Announce a Collaboration Focused on MicroRNA-Based Diagnostics
6. Rosetta Genomics and M. D. Anderson to Develop a MicroRNA-based Diagnostic Test to Identify Risk of Recurrence of Lung Cancer
7. Rosetta Genomics Signs Agreement With West Coast CLIA Certified Lab to Develop and Validate Tests Applying Companys MicroRNA Technology
8. Columbia University Medical Center and Rosetta Genomics Announce Columbia Universitys Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica
9. Eularis Releases First-Ever Study on ROI of Pre-Launch Named Patient Programmes
10. F.D.A. Approves SANCUSO(R), the First and Only Patch for Preventing Nausea and Vomiting in Cancer Patients Undergoing Chemotherapy
11. The First Direct Structural Evidence of SV2A has Been Revealed Thanks to Protein Tomography(TM), and Published in BBRC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... 2015  Results from an interim analysis of ... 5g of idarucizumab enabled emergency surgery to be ... with dabigatran (Pradaxa ® dabigatran etexilate mesylate). The ... of dabigatran enabled patients to be urgently brought ... 1.7 hours between administration of idarucizumab and start ...
(Date:9/1/2015)... Mass. , Sept. 1, 2015   ... a next-generation infusion management system, closed on a ... investor WuXi Healthcare Ventures. Cardinal Partners, CICA, Inc., ... also participated in the round. This financing will ... global infusion market. Leerink Partners LLC acted as ...
(Date:9/1/2015)... 1, 2015 Within just two years after ... has rapidly reached 3,000 employees worldwide. This increase ... the injectable drug delivery market and SHL,s effective ... leader in the design and manufacturing of auto ... robust manufacturing capabilities, a lean supply chain, strong ...
Breaking Medicine Technology:New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 2New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 3New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 4New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 5New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 6New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 7New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 8New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 9Ivenix Inc. Secures $42 Million in Funding 2Ivenix Inc. Secures $42 Million in Funding 3SHL Group Reaches Major Milestone of 3000 Employees 2
(Date:9/2/2015)... ... September 02, 2015 , ... “ G-Hold ” was featured on ... technology products available to consumers. Amanda Forstrom, a technology expert and special reporter for ... people to comfortably hold a tablet while reducing the likelihood of it dropping. , ...
(Date:9/2/2015)... ... September 02, 2015 , ... Please ... Aneurysm Awareness Month , which was established by the Foundation in 2007 with ... education, and helping fund more research remains our top priority,” commented Christine Buckley, ...
(Date:9/2/2015)... SC (PRWEB) , ... September 02, 2015 , ... ... announced today that he is now certified in “Systema”: a Russian martial art system ... aspects of life. , Systema , which dates back to the 10th ...
(Date:9/2/2015)... ... September 02, 2015 , ... Traveling to the Caribbean can be an ... flora and fauna. , Lifestyle Holidays Vacation Club knows that Puerto ... travelers experience that much better, Lifestyle Holidays Vacation Club has put together its list ...
(Date:9/1/2015)... ... September 01, 2015 , ... For many men, the first thing they notice when they go ... to wear a looser fitting shirt with a collar that doesn’t close against the skin, ... their collar and skin all day because it’s uncomfortable. Now men in suits will ...
Breaking Medicine News(10 mins):Health News:Comfortably Hold a Tablet with G-Hold Hands Free Tablet Holder 2Health News:September Celebrated as Brain Aneurysm Awareness Month 2Health News:Dr. Robert G. Schwartz Achieves Certification in Russian Martial Art “Systema” and Focuses on Integrating Techniques & Principles into Health Care Delivery 2Health News:Dr. Robert G. Schwartz Achieves Certification in Russian Martial Art “Systema” and Focuses on Integrating Techniques & Principles into Health Care Delivery 3Health News:Lifestyle Holidays Vacation Club Lists 3 Things to Consider When On a Puerto Plata Vacation 2Health News:Lifestyle Holidays Vacation Club Lists 3 Things to Consider When On a Puerto Plata Vacation 3Health News:Getting Rid of Double Chins: New FDA Approved Kybella Treatment Proving Very Popular Among Professional Men at Crutchfield Dermatology 2
... October 5, 2011 The Merck Childhood Asthma ... million in funding to implement the Community Healthcare ... partnership in five non-profit, Federally Qualified Health Centers. ... designed to demonstrate how asthma management tools proven ...
... (October 4, 2011)In a new study led by Fox ... have found that Gleason scores determined by pathologists at ... of recurrence than Gleason scores from referring institutions. ... Meeting of the American Society for Radiation Oncology on ...
... of Adelaide shows the parents of women with polycystic ovary syndrome ... PCOS is a hormonal disorder affecting about 10% of women ... endocrine disorders in women and a leading cause of infertility. ... to have any form of cardiovascular disease, and almost twice as ...
... TUESDAY, Oct. 4 (HealthDay News) -- Heart patients who have stenting ... they are released the same day as if they are sent ... "[Discharging patients the same day] wasn,t associated with any increased risk ... study appearing in the Oct. 5 issue of the Journal ...
... , WEDNESDAY, Oct. 5 (HealthDay News) -- Three hours of ... risk by 22 percent, a new study suggests. The ... 38 percent of that decreased risk was due to the ... high-density lipoprotein (HDL) cholesterol. The findings were published Oct. ...
... TUESDAY, Oct. 4 (HealthDay News) -- ,A common structural variation ... able to remember details of past events and to distinguish ... have imagined, scientists report. The study included 53 healthy ... Participants who lacked a fold at the front of the ...
Cached Medicine News:Health News:Childhood asthma non-profit invests millions in health centers to help children better manage asthma 2Health News:Childhood asthma non-profit invests millions in health centers to help children better manage asthma 3Health News:Fox Chase Gleason scores better predict prostate cancer's recurrence after radiation 2Health News:Fox Chase Gleason scores better predict prostate cancer's recurrence after radiation 3Health News:Overnight Stay May Not Be Necessary for Stenting: Study 2Health News:Overnight Stay May Not Be Necessary for Stenting: Study 3Health News:MRI Study Unfolds Clues to Memory 2
VISCO SHIELD Viscoelastic. Complete with 23g x 7/8" Thin Wall Cannula....
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
Medicine Products: